Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference15 articles.
1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010
2. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MED/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Welhelm;Cancer Res,2004
3. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell line;Ulivi;J Cell Physiol,2009
4. Sorafenib is advanced clear-cell renal -cell carcinoma;Escudier;N Engl J Med,2007
5. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial;Escudier;J Clin Oncol,2009
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial;Cancer Chemotherapy and Pharmacology;2023-04-03
2. Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors;Cancer Chemotherapy and Pharmacology;2023-02-25
3. Everolimus therapy and side‑effects: A systematic review and meta‑analysis;International Journal of Oncology;2021-06-15
4. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations;Cells;2019-12-06
5. Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study;European Journal of Cancer;2017-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3